-
Je něco špatně v tomto záznamu ?
Portal Vein Embolization (PVE) Versus PVE with Haematopoietic Stem Cell Application in Patients with Primarily Non-resectable Colorectal Liver Metastases
V. Treska, J. Fichtl, J. Ludvik, J. Bruha, V. Liska, I. Treskova, R. Kucera, O. Topolcan, D. Lysak, T. Skalicky, J. Ferda,
Jazyk angličtina Země Řecko
Typ dokumentu srovnávací studie, časopisecké články
NLK
Free Medical Journals
od 2004 do Před 2 roky
Open Access Digital Library
od 2004-01-01
- MeSH
- časové faktory MeSH
- Kaplanův-Meierův odhad MeSH
- kolorektální nádory mortalita patologie MeSH
- kombinovaná terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory jater mortalita sekundární terapie MeSH
- přežití bez známek nemoci MeSH
- regenerace jater * MeSH
- retrospektivní studie MeSH
- rizikové faktory MeSH
- senioři MeSH
- terapeutická embolizace škodlivé účinky metody MeSH
- transplantace hematopoetických kmenových buněk * škodlivé účinky mortalita MeSH
- transplantace mezenchymálních kmenových buněk * škodlivé účinky mortalita MeSH
- vena portae * MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
BACKGROUND: Portal vein embolization (PVE) and PVE with autologous mesenchymal stem cell application (PVE-MSC) increases future liver remnant volume (FLRV). The aim of this study was to compare both methods from the aspect of FLRV growth, progression of colorectal liver metastases (CLM), CLM resectability and long-term results. PATIENTS AND METHODS: Fifty-five patients with CLM and insufficient FLRV were included in the study. FLVR growth and CLM volume were evaluated using computed tomography. Liver resection was performed in patients with FLVR >30% of total liver volume. RESULTS: In the PVE (N=27) group, FLRV growth was observed in 23 patients (85.2%) and in 100% of patients in the PVE-MSC (N=28) group (p<0.05). The rapidity of FLRV and CLM growth did not differ between groups. R0 resection was performed in 14 (51.8%) and 24 (85.7%) patients from the PVE and PVE-MSC (p<0.02) groups, respectively. The 3-year overall and progression-free survival rates were 85.75% and 9.3% in the PVE group and 68.7% and 17.1% in the PVE-MSC group, respectively (p<0.67 and p<0.84, respectively). CONCLUSION: PVE-MSC allows for more effective growth of FLRV and resectability of CLM compared to PVE. The two methods do not differ in their long-term results.
Department of Hemato oncology University Hospital Faculty of Medicine Pilsen Czech Republic
Department of Immunochemistry University Hospital Faculty of Medicine Pilsen Czech Republic
Department of Radiology University Hospital Faculty of Medicine Pilsen Czech Republic
Department of Surgery University Hospital Faculty of Medicine Pilsen Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18032981
- 003
- CZ-PrNML
- 005
- 20181009105640.0
- 007
- ta
- 008
- 181008s2018 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/anticanres.12888 $2 doi
- 035 __
- $a (PubMed)30194213
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Treska, Vladislav $u Department of Surgery, University Hospital, Faculty of Medicine, Pilsen, Czech Republic treska@fnplzen.cz.
- 245 10
- $a Portal Vein Embolization (PVE) Versus PVE with Haematopoietic Stem Cell Application in Patients with Primarily Non-resectable Colorectal Liver Metastases / $c V. Treska, J. Fichtl, J. Ludvik, J. Bruha, V. Liska, I. Treskova, R. Kucera, O. Topolcan, D. Lysak, T. Skalicky, J. Ferda,
- 520 9_
- $a BACKGROUND: Portal vein embolization (PVE) and PVE with autologous mesenchymal stem cell application (PVE-MSC) increases future liver remnant volume (FLRV). The aim of this study was to compare both methods from the aspect of FLRV growth, progression of colorectal liver metastases (CLM), CLM resectability and long-term results. PATIENTS AND METHODS: Fifty-five patients with CLM and insufficient FLRV were included in the study. FLVR growth and CLM volume were evaluated using computed tomography. Liver resection was performed in patients with FLVR >30% of total liver volume. RESULTS: In the PVE (N=27) group, FLRV growth was observed in 23 patients (85.2%) and in 100% of patients in the PVE-MSC (N=28) group (p<0.05). The rapidity of FLRV and CLM growth did not differ between groups. R0 resection was performed in 14 (51.8%) and 24 (85.7%) patients from the PVE and PVE-MSC (p<0.02) groups, respectively. The 3-year overall and progression-free survival rates were 85.75% and 9.3% in the PVE group and 68.7% and 17.1% in the PVE-MSC group, respectively (p<0.67 and p<0.84, respectively). CONCLUSION: PVE-MSC allows for more effective growth of FLRV and resectability of CLM compared to PVE. The two methods do not differ in their long-term results.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a kolorektální nádory $x mortalita $x patologie $7 D015179
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a terapeutická embolizace $x škodlivé účinky $x metody $7 D004621
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a transplantace hematopoetických kmenových buněk $x škodlivé účinky $x mortalita $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a nádory jater $x mortalita $x sekundární $x terapie $7 D008113
- 650 12
- $a regenerace jater $7 D008115
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a transplantace mezenchymálních kmenových buněk $x škodlivé účinky $x mortalita $7 D045164
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a vena portae $7 D011169
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Fichtl, Jakub $u Department of Surgery, University Hospital, Faculty of Medicine, Pilsen, Czech Republic.
- 700 1_
- $a Ludvik, Jaroslav $u Department of Radiology, University Hospital, Faculty of Medicine, Pilsen, Czech Republic.
- 700 1_
- $a Bruha, Jan $u Department of Surgery, University Hospital, Faculty of Medicine, Pilsen, Czech Republic.
- 700 1_
- $a Liska, Vaclav $u Department of Surgery, University Hospital, Faculty of Medicine, Pilsen, Czech Republic.
- 700 1_
- $a Treskova, Inka $u Department of Surgery, University Hospital, Faculty of Medicine, Pilsen, Czech Republic.
- 700 1_
- $a Kucera, Radek $u Department of Immunochemistry, University Hospital, Faculty of Medicine, Pilsen, Czech Republic.
- 700 1_
- $a Topolcan, Ondrej $u Department of Immunochemistry, University Hospital, Faculty of Medicine, Pilsen, Czech Republic.
- 700 1_
- $a Lysak, Daniel $u Department of Hemato-oncology, University Hospital, Faculty of Medicine, Pilsen, Czech Republic.
- 700 1_
- $a Skalicky, Tomas $u Department of Surgery, University Hospital, Faculty of Medicine, Pilsen, Czech Republic.
- 700 1_
- $a Ferda, Jiri $u Department of Radiology, University Hospital, Faculty of Medicine, Pilsen, Czech Republic.
- 773 0_
- $w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 38, č. 9 (2018), s. 5531-5537
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30194213 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181009110128 $b ABA008
- 999 __
- $a ok $b bmc $g 1339970 $s 1029975
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 38 $c 9 $d 5531-5537 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
- LZP __
- $a Pubmed-20181008
